Xcovery: Vorolanib by Xcovery Holding for Small-Cell Lung Cancer: Likelihood of Approval
Vorolanib is under clinical development by Xcovery Holding and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,... The post Vorolanib by Xcovery Holding for Small-Cell Lung Cancer: Likelihood of Approval appeared first on Pharmaceutical Technology.
Read full article »
Xcovery is a Florida-based biopharmaceutical company that develops and commercializes ALK kinase inhibitors for the treatment of cancer.
Read more